DRUGSwww.epgonline.orgDISEASE KNOWLEDGE CENTRESwww.epgonline.orgGUIDELINESwww.epgonline.orgCLINICAL TRIALSwww.epgonline.orgMEDICAL NEWSwww.epgonline.orgLINKSwww.epgonline.org
Members Login
How to use the
Email

Password



EPG News Feed Medical News
EPG Online Disease Knowledge Centres Feed Disease Knowledge
Recent UK Drug Updates Drug Updates
EPG Search
Frequent Searches:
Search
Languages

Medical News Headlines
Expert praises Parkinson's treatment
The treatment of Parkinson's disease with levodopa has been discussed...
Published Thursday 04 December 2008

Annual report finds cancer initiative a success
A new initiative that aims to improve the treatment of...
Published Thursday 04 December 2008

New game could help tackle obesity and diabetes in kids, expert claims
A new scheme from the British Heart Foundation (BHF) will...
Published Thursday 04 December 2008

Some "good cholesterol" not good enough, study suggests
A number of preconceptions about "good" HDL cholesterol have been...
Published Tuesday 02 December 2008

More Medical News
Browse Other Languages
The NSCLCs account for 80% of all lung cancers and can be further subdivided into squamous-cell carcinoma, large-cell carcinoma and adenocarcinoma (which includes bronchioloalveolar-cell carcinoma [BAC] Pharmacologic management of asthma aims to control symptoms, prevent exacerbations and provide the best possible pulmonary function with minimal medications, side effects and risk factors. Insomnia, hormones released in the body are involved in certain aspects of homeostasis, including regulating the circadian rhythms established by the SCN of the hypothalamus. Gastrointestinal stromal tumours (GISTs) are the most common mesenchymal tumours of the gastrointestinal (GI) tract.
More NewsEPG Online News
Disease related news: Omega-3 free fatty acids 'do not prevent Crohn's disease relapse'
10 Apr 2008

Omega-3 free fatty acids supplements do not appear to prevent relapse in Crohn's disease patients, a study shows.

A team at the University of Western Ontario conducted two large-scale trials of high-dose omega-3 free fatty acids as maintenance therapy in patients with Crohn's disease in remission.

The studies, Epanova Program in Crohn's Study 1 (EPIC-1) and EPIC-2, were carried out at 98 centres in Canada, Europe, Israel and the US.

Patients were randomly assigned either 4 g of omega-3 free fatty acids or placebo for up to 58 weeks.

Some 188 EPIC-1 patients received omega-3 free fatty acids and 186 patients received placebo, while 189 patients received omega-3 free fatty acids and 190 received placebo in the EPIC-2 study.

No significant difference in relapse rates was found between the two groups in either trial, with 54 patients treated with omega-3 free fatty acids and 62 patients receiving placebo experiencing a clinical relapse in EPIC-1. In the EPIC-2 group 84 patients experienced relapse (compared with 94 patients treated with placebo).

In EPIC-1 31.6 per cent of patients receiving omega-3 free fatty acids experienced a relapse within 360 days (compared with 35.7 per cent in the placebo group), while in EPIC-2 this was 47.8 per cent (compared with 48.8 per cent of placebo patients).

The study's authors claimed that the results were important as the use of alternative medicines and omega-3 free fatty acid formulations is widespread among patients with inflammatory bowel disease.

"Given the negative results observed in the EPIC trials and in [other trials], we do not endorse this practice, since patients with Crohn's disease who are at risk for relapse would be better served by taking medications of known efficacy," they concluded.

Previous clinical trials to evaluate omega-3 free fatty acids for maintenance of remission in Crohn's disease have hitherto been inconsistent.

The study is reported in the April 9th issue of JAMA.

Click here for EPG Online Physician's tools including disease awareness, diagnosis tools, treatment options and management guidance.ADNFCR-1419-ID-18544936-ADNFCR

Print Article    Bookmark Bookmark
Related News Stories (Clinical / Disease-specific News)

FEATURES

DRUG UPDATES Drug updates feed

EMAIL BULLETINS

MEDICAL NEWS EPG News Feed

DISEASE CENTRES Disease Centres feed

RESEARCH

GOOGLE SEARCH

GUIDELINES

DRUG DATA UK Drug Data Feed